<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Persistently elevated <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> and positive <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LAC) are associated with an increased risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The objective of this study was to explore whether <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> and/or LAC positivity were associated with the traditional risk factors for <z:mp ids='MP_0005048'>thrombosis</z:mp> or with medication use in patients without <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> hospitalised with arterial or <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN: Cross-sectional study </plain></SENT>
<SENT sid="3" pm="."><plain>SETTING: Montefiore Medical Center, a large urban tertiary care centre </plain></SENT>
<SENT sid="4" pm="."><plain>PATIENTS: 270 patients (93 with <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> (DVT) or <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> (PE), and 177 with non-haemorrhagic <z:hpo ids='HP_0001297'>stroke</z:hpo> (<z:hpo ids='HP_0001297'>cerebrovascular accident</z:hpo> (<z:chebi fb="4" ids="46274">CVA</z:chebi>)) admitted between January 2006 and December 2010 with a discharge diagnosis of either DVT, PE or <z:chebi fb="4" ids="46274">CVA</z:chebi>, who had LAC and <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> measured within 6 months from their index admission </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> or <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> were excluded </plain></SENT>
<SENT sid="6" pm="."><plain>MAIN OUTCOME MEASURES: The main dependent variable was <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> of 40 units or greater (<z:hpo ids='HP_0003613'>antiphospholipid antibody positivity</z:hpo>) and/or LAC positivity </plain></SENT>
<SENT sid="7" pm="."><plain>Independent variables were traditional <z:mp ids='MP_0005048'>thrombosis</z:mp> risk factors, <z:chebi fb="0" ids="35664">statin</z:chebi> use, aspirin use and <z:chebi fb="8" ids="10033">warfarin</z:chebi> use </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: 31 (11%) patients were LAC positive and/or <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> positive </plain></SENT>
<SENT sid="9" pm="."><plain>None of the traditional risk factors at the time of DVT/PE/<z:chebi fb="4" ids="46274">CVA</z:chebi> was associated with <z:hpo ids='HP_0003613'>antiphospholipid antibody positivity</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Current <z:chebi fb="0" ids="35664">statin</z:chebi> use was associated with an OR of 3.2 (95% CI 1.3 to 7.9, p=0.01) of <z:hpo ids='HP_0003613'>antiphospholipid antibody positivity</z:hpo>, adjusted for age, ethnicity and gender </plain></SENT>
<SENT sid="11" pm="."><plain>Aspirin or <z:chebi fb="8" ids="10033">warfarin</z:chebi> use was not associated with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> levels </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: If <z:chebi fb="0" ids="35664">statin</z:chebi> therapy reflects the history of previous <z:e sem="disease" ids="C0020473" disease_type="Disease or Syndrome" abbrv="">hyperlipidaemia</z:e>, high levels of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> may be a marker for earlier endothelial damage caused by <z:e sem="disease" ids="C0020473" disease_type="Disease or Syndrome" abbrv="">hyperlipidaemia</z:e> </plain></SENT>
</text></document>